DANONE (BSN.DE) Stock Fundamental Analysis

FRA:BSN • FR0000120644

69.06 EUR
-0.98 (-1.4%)
Last: Feb 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Overall BSN gets a fundamental rating of 5 out of 10. We evaluated BSN against 62 industry peers in the Food Products industry. While BSN belongs to the best of the industry regarding profitability, there are concerns on its financial health. BSN has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year BSN was profitable.
  • In the past year BSN had a positive cash flow from operations.
  • BSN had positive earnings in each of the past 5 years.
  • Each year in the past 5 years BSN had a positive operating cash flow.
BSN.DE Yearly Net Income VS EBIT VS OCF VS FCFBSN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 4.20%, BSN is in the better half of the industry, outperforming 66.13% of the companies in the same industry.
  • BSN has a better Return On Equity (11.59%) than 69.35% of its industry peers.
  • With a decent Return On Invested Capital value of 6.83%, BSN is doing good in the industry, outperforming 66.13% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 6.69%.
  • The last Return On Invested Capital (6.83%) for BSN is above the 3 year average (6.38%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.2%
ROE 11.59%
ROIC 6.83%
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
BSN.DE Yearly ROA, ROE, ROICBSN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • BSN has a better Profit Margin (6.72%) than 75.81% of its industry peers.
  • BSN's Profit Margin has been stable in the last couple of years.
  • BSN's Operating Margin of 13.25% is amongst the best of the industry. BSN outperforms 80.65% of its industry peers.
  • BSN's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 50.47%, BSN belongs to the best of the industry, outperforming 83.87% of the companies in the same industry.
  • BSN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.25%
PM (TTM) 6.72%
GM 50.47%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
BSN.DE Yearly Profit, Operating, Gross MarginsBSN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • BSN has more shares outstanding than it did 1 year ago.
  • BSN has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BSN has been reduced compared to a year ago.
BSN.DE Yearly Shares OutstandingBSN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
BSN.DE Yearly Total Debt VS Total AssetsBSN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 2.43 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BSN (2.43) is comparable to the rest of the industry.
  • BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
  • BSN has a Debt to FCF ratio of 5.07. This is in the better half of the industry: BSN outperforms 72.58% of its industry peers.
  • A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
  • BSN has a worse Debt to Equity ratio (0.83) than 69.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF 5.07
Altman-Z 2.43
ROIC/WACC1.07
WACC6.4%
BSN.DE Yearly LT Debt VS Equity VS FCFBSN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • BSN has a Current Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BSN has a Current ratio of 0.95. This is in the lower half of the industry: BSN underperforms 70.97% of its industry peers.
  • A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.78, BSN is in line with its industry, outperforming 43.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.78
BSN.DE Yearly Current Assets VS Current LiabilitesBSN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
  • BSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.17% yearly.
  • BSN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.54%.
  • The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.09% on average over the next years.
  • The Revenue is expected to grow by 2.86% on average over the next years.
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.09%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BSN.DE Yearly Revenue VS EstimatesBSN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 10B 20B 30B
BSN.DE Yearly EPS VS EstimatesBSN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 18.47, BSN is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Earnings ratio of BSN is on the same level as its industry peers.
  • BSN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • BSN is valuated correctly with a Price/Forward Earnings ratio of 16.56.
  • The rest of the industry has a similar Price/Forward Earnings ratio as BSN.
  • BSN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.69, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 18.47
Fwd PE 16.56
BSN.DE Price Earnings VS Forward Price EarningsBSN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, BSN is valued a bit cheaper than the industry average as 67.74% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 16.4
EV/EBITDA 9.95
BSN.DE Per share dataBSN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.45
PEG (5Y)N/A
EPS Next 2Y7.18%
EPS Next 3Y7.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • BSN has a Yearly Dividend Yield of 2.99%.
  • BSN's Dividend Yield is a higher than the industry average which is at 3.02.
  • Compared to an average S&P500 Dividend Yield of 1.80, BSN pays a better dividend.
Industry RankSector Rank
Dividend Yield 2.99%

5.2 History

  • The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
BSN.DE Yearly Dividends per shareBSN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

  • 74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
  • The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP74.99%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
BSN.DE Yearly Income VS Free CF VS DividendBSN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
BSN.DE Dividend Payout.BSN.DE Dividend Payout, showing the Payout Ratio.BSN.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

DANONE

FRA:BSN (2/11/2026, 7:00:00 PM)

69.06

-0.98 (-1.4%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)10-07
Earnings (Next)02-20
Inst Owners54.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap47.06B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts75.33
Price Target80.67 (16.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.99%
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.23%
PT rev (3m)1.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.43%
EPS NY rev (3m)-0.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE 18.47
Fwd PE 16.56
P/S 1.72
P/FCF 16.4
P/OCF 12.24
P/B 2.97
P/tB N/A
EV/EBITDA 9.95
EPS(TTM)3.74
EY5.42%
EPS(NY)4.17
Fwd EY6.04%
FCF(TTM)4.21
FCFY6.1%
OCF(TTM)5.64
OCFY8.17%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.45
PEG (5Y)N/A
Graham Number44.26
Profitability
Industry RankSector Rank
ROA 4.2%
ROE 11.59%
ROCE 12.02%
ROIC 6.83%
ROICexc 8.36%
ROICexgc 50.58%
OM 13.25%
PM (TTM) 6.72%
GM 50.47%
FCFM 10.49%
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF 5.07
Debt/EBITDA 2.71
Cap/Depr 77.72%
Cap/Sales 3.57%
Interest Coverage 23.53
Cash Conversion 78.8%
Profit Quality 156.01%
Current Ratio 0.95
Quick Ratio 0.78
Altman-Z 2.43
F-Score8
WACC6.4%
ROIC/WACC1.07
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.09%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.93%
EBIT Next 3Y14.73%
EBIT Next 5Y10.6%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%

DANONE / BSN.DE FAQ

What is the fundamental rating for BSN stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.


What is the valuation status for BSN stock?

ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.


How profitable is DANONE (BSN.DE) stock?

DANONE (BSN.DE) has a profitability rating of 7 / 10.


What is the earnings growth outlook for DANONE?

The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.53% in the next year.


Is the dividend of DANONE sustainable?

The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 74.99%.